European Commission Approves Pembrolizumab in MSI-H/dMMR Solid Tumors

Article

Pembrolizumab has been approved by the European Commission in 5 indications of solid tumors that are microsatellite instability–high or deficient mismatch repair.

Pembrolizumab (Keytruda) has been approved by the European Commission for patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) tumors, according to a press release from Merck.

The approval is based on results from the phase 2 KEYNOTE-164 trial (NCT02460198)— assessing the monotherapy in patients with previously treated locally advanced unresectable of metastatic colorectal cancer—and the phase 2 KEYNOTE-158 trial (NCT02628067)—examining pembrolizumab in advanced solid tumors.

Patients with colorectal cancer (n = 124) had an objective response rate (ORR) of 34.0% (95% CI, 25.6%-42.9%) with a complete response (CR) rate of 10.0% after a median follow-up of 37.3 months. After a median follow-up of 21.9 years, those with endometrial cancer (n = 83) had an ORR of 51.0% (95% CI, 39.4%-61.8%), a CR rate of 16.0%. Those with gastric cancer (n = 51) had an ORR of 37.0% (95% CI, 24.1%-51.9%), with a CR rate of 14.0% after a median follow-up of 13.9 months. Those with small intestine cancer (n = 27) had an ORR of 56.0% (95% CI, 35.3%-74.5%), with a CR rate of 15.0% and a median follow-up of 29.1 months. Those with biliary cancer (n = 22) had an ORR of 41.0% (95% CI, 20.7%-63.6%), with a CR rate of 14.0%, and a median follow-up of 19.4 months.

“The [European Commission] approval of [pembrolizumab] is an important milestone for patients living with these MSI-H/dMMR cancers who have had few treatment options and face worse outcomes when diagnosed at an advanced stage,” Aurélien Marabelle, MD, PhD, immuno-oncologist at Gustave Roussy Cancer Center and Professor of Clinical Immunology at the University of Paris Saclay, said in the press release.

Reference

European Commission approved Merck’s Keytruda (pembrolizumab) for patients with microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) tumors in five different types of cancer. News Release. Merck. April 29, 2022. Accessed May 6, 2022. https://bit.ly/3waOTJz

Recent Videos
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to expect at the 43rd Annual Chemotherapy Foundation Symposium, such as new chemotherapeutics and targeted therapies.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Related Content
Results from the TRANSCEND NHL 001 trial showed that liso-cel achieved an ORR of 82.7% in patients with previously treated mantle cell lymphoma.

EU Approves Liso-Cel in R/R MCL With ≥ 2 Prior Lines of Systemic Therapy

Tim Cortese
November 25th 2025
Article

Results from the TRANSCEND NHL 001 trial showed that liso-cel achieved an ORR of 82.7% in patients with previously treated mantle cell lymphoma.

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

Parkinson's disease patient, Arthritis hand, gout knee pain, or mental health care with geriatric doctor consulting examining comforting elderly senior aged adult in medical exam clinic or hospital | © Chinnapong - stock.adobe.com

How Does Decision-Making Capacity, Patient-Centered Care Inform Oncology Decisions?

Ariana Pelosci
November 25th 2025
Article

When a patient may not have the capability of understanding or consenting to treatment options, Louis P. Voigt, MD, and Yesne Alici, MD, will utilize decision-making capacity techniques.

Experts discussed supportive care and why it should be integrated into standard oncology care.

How Supportive Care Methods Can Improve Oncology Outcomes

Declan Walsh, MD;Denise B. Reynolds, RD;Adam Friedman, MD, FAAD;Daniel C. McFarland, DO;Michelle Fingeret, PhD;Christian J. Nelson, PhD;William S. Breitbart, MD
November 10th 2025
Podcast

Experts discussed supportive care and why it should be integrated into standard oncology care.

Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors

Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors

Ariana Pelosci
November 21st 2025
Article

Partial responses and stable disease were observed with PAS-004 in patients with advanced solid tumors harboring RAS, NF1, or RAF mutations.

Results from the C-POST trial showed that cemiplimab improved DFS vs placebo in patients with CSCC at high risk of recurrence following surgery and radiation.

EC Approves Adjuvant Cemiplimab in CSCC at High Risk of Recurrence

Tim Cortese
November 20th 2025
Article

Results from the C-POST trial showed that cemiplimab improved DFS vs placebo in patients with CSCC at high risk of recurrence following surgery and radiation.